Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile.
Gonzalez-Martin A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andres R, Alvarez I, Aramenda JM, Ayala de la Pena F, Barnadas A, Batista N, Calvo L, Galve E, Garcia-Palomo A, Garcia-Saenz, JA, de la Haba J, Lopez R, Lopez-Vivanco G, Martinez-Janez N, Martinez de Duenas E, Plazaola A, Rodriguez-Lescure A, Ruiz M, Sanchez-Rovira P, Santaballa A,Segui MA, Tusquets I, Zamora P, Martin M.
Current Cancer Drug Targets. 2016; 16: 415-428. FI: 2,992 (Q3).
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.
Breast Cancer Research And Treatment. 2016; 156: 81-89. FI: 3,626 (Q2).
Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Rigo-Bonnin R, Cobo-Sacristán S, Gonzalo-Diego N, Colom H, Muñoz-Sánchez C, Urruticoechea A, Falo C, Alía P.
J Pharmaceut Biomed. 2016; 117: 140-149. FI: 3,255 (Q1).
Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer.
Ocana A, Templeton AJ, Casas M, Sanchez-Arago M, Caballero R, Rodriguez A, Ruiz A, Alba E, Calvo L, Ruiz M, Santaballa A, Rodriguez C, Crespo C, Ramos M, Gracia JM, Lluch-Hernandez A, Alvarez I, Carrasco E, Amir E, Martin M.
Annals Of Oncology. 2016; 27: -. FI: 11,855 (Q1).
Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.
Romero I, Churruca CM, Redondo A, Santaballa A, Calvo E, Ojeda B, Del Campo JM, Lainez N, Garcia-Martinez E, Romeo M, Bover I, Mendiola C, Caballero C, Martinez J, Herrero A, Sanchez AB, De Juan A, Hernando S, Lopez-Guerrero JA, Poveda A, GEICO.
J. Clin. Oncol. 2015; 33. FI: 18.428 (Q1).
Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?.
Ciria JP, Eguiguren M, Cafiero S, Uranga I, Diaz de Cerio I, Querejeta A, Urraca JM, Minguez J, Guimon E, Puertolas JR.
Rep Pract Oncol Radiother. 2015; 20: 1-11. FI: 0.000 (Q0).
Mediastinal mature teratoma with somatic-type malignancies.
Comba J, Cancho G, Caballero C, Rezola M, Gomez MC., Lobo C, Silva M, Segues N, Juaristi A, Garmendia M, Ruiz I.
Virchows Arch. 2014; 465: 335-0. FI: 2.560 (Q2).
Immunohistochemical expression of GATA 3 in vulvar Paget disease.
Gomez MDC, Ruiz I, Rezola M, Caballero MC, Silva MJ.
Virchows Arch. 2014; 465: 356-0. FI: 2.560 (Q2).
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy.
Gamez-Pozo A, Perez Carrion RM, Manso L, Crespo C, Mendiola C, Lopez-Vacas R, Berges-Soria J, Alvarez Lopez I, Margeli M, Bayo Calero JL, Gonzalez X, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalan G, Alvarez JV, Miramon J, Salvador FJ, Ruiz M, Espinosa E, Vara JA, Fresno P.
PLoS One. 2014; 9: e109611. FI: 3.534 (Q1).
Treatment innovations for metastatic breast cancer: Nanopartiele albumin-bound (NAB) technology targeted to tumors.
Lluch A, Alvarez I, Munoz M, Angel Segui M, Tusquets I, Garcia-Estevez L.
CRIT REV ONCOL HEMAT. 2014; 89: 62-72. FI: 4.046 (Q1).
Finding the right dose of fulvestrant in breast cancer.
Estevez L, Alvarez I, Tusquets I, Segui MA, Munoz M, Fernandez Y, Lluch A.
Cancer Treat. Rev. 2013; 39: 136-141. FI: 6.024 (Q1).
SEOM clinical guidelines for the management of metastatic breast cancer 2013.
Llombart-Cussac A, de la Haba J, Ruiz A, Alvarez I, Cortes J.
Clin. Transl. Oncol. 2013; 15: 1004-1010. FI: 1.276 (Q4).
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Alvarez Lopez I, Dorca J, Martinez S, Batista Lopez N, Dominguez Fernandez S, Cuyas E, Visa J, Rodriguez-Gallego E, Quirantes-Pine R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA, Metten 10 Investigators.
Oncotarget. 2013; 4: 1484-1495. FI: 6.636 (Q1).
Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.
Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, Margeli Vila M, Anton A, Rodriguez-Lescure A, Segui-Palmer MA, Munoz-Mateu M, Dorca Ribugent J, Lopez-Vega JM, Jara C, Espinosa E, Mendiola Fernandez C, Andres R, Ribelles N, Plazaola A, Sanchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacon JI, Rodriguez CA, Hernando B, Alvarez I, Carrasco E, Lluch A.
J. Clin. Oncol. 2013; 31: 2593-2599. FI: 18.038 (Q1).
